Appendix 18d: Computerised cognitive behavioural therapy for panic disorder GRADE evidence profiles

Similar documents
1 CCBT for Panic Disorder

APPENDIX 33: HEALTH ECONOMICS ECONOMIC EVIDENCE PROFILES

Costs: description and values Outcomes: description and values. Costs: Consultations with psychologists, psychiatrists, GPs

1 High intensity psychological interventions for generalised anxiety disorder

Sepsis. National Clinical Guideline Centre. Sepsis: the recognition, diagnosis and management of sepsis. NICE guideline <number> January 2016

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Setting The setting was secondary care. The economic study appears to have been conducted in the UK.

The Cost-Effectiveness of Individual Cognitive Behaviour Therapy for Overweight / Obese Adolescents

Managing knowledge to support appropriate use of health technologies: some insights from the UK National Health Service

Basic Economic Analysis. David Epstein, Centre for Health Economics, York

Cost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M

Digital IAPT: the effectiveness & costeffectiveness

Resubmission. Scottish Medicines Consortium

Technology appraisal guidance Published: 22 February 2006 nice.org.uk/guidance/ta97

Lead team presentation Eluxadoline for treating irritable bowel syndrome with diarrhoea (STA)

Is an internet based (Behavioural Activation) treatment for post-natal depression (MUMiCBT) effective in reducing symptoms of depression?

Setting The setting was secondary care. The economic study was conducted in the USA.

An Introduction to Costeffectiveness

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380

Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416

Clinical efficacy and economic evaluation of internet cognitive behavioural therapy for major depressive disorder

How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E

Technology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547

Critical Appraisal Skills. Professor Dyfrig Hughes Health Economist AWMSG

Setting The setting was primary care. The economic study was carried out in the UK.

Setting The setting was secondary care. The economic study was carried out in the UK.

Slides for Committee CIC redacted

Technology appraisal guidance Published: 23 September 2015 nice.org.uk/guidance/ta355

Source of effectiveness data The estimate for final outcomes was based on a synthesis of completed studies.

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

Setting The setting was outpatient, secondary care. The economic study was carried out in the UK.

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442

Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200

Multiple sclerosis. National Clinical Guideline Centre. Management of multiple sclerosis in primary and secondary care. Clinical Guideline 186

Setting The setting was the community. The economic study was carried out in the USA.

Setting The setting was primary and secondary care. The economic study was carried out in Canada.

Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD Narayan S, Hay J

Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367

WHAT TO DO IN ABSENCE OF HEAD TO HEAD CLINICAL TRIAL DATA. Lead the economic evaluation group at CHERE, University of Technology, Sydney

In keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:

Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352

Link between effectiveness and cost data The effectiveness and cost data came from the same sample of patients and were prospectively evaluated.

Technology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247

Technology appraisal guidance Published: 18 April 2018 nice.org.uk/guidance/ta518

Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455

1 Executive summary. Background

Summary 1. Comparative effectiveness

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview

Decision-Analytic Modeling of PSA Screening an ONCOTYROL Project

Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy

Technology appraisal guidance Published: 26 September 2012 nice.org.uk/guidance/ta264

Discussion of meta-analysis on the benefits of psychotherapy

Technology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta260

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440

Technology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275

Technology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312

Health technology The use of oseltamivir for the treatment of influenza in otherwise healthy children.

Objectives. Context. Wider NHS context 5/24/2017. Technology in palliative care. Technology enabled Care (TEC)

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471

Technology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta345

Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta228

Outcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of:

Evidence profile. Physical Activity. Background on the scoping question. Population/Intervention/Comparison/Outcome (PICO)

Setting The setting was secondary care. The economic study was conducted in Australia.

Type of intervention Screening and treatment. Economic study type Cost-utility analysis.

Health Economics 101: PPI prescriptions in the Emergency Room

Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta323

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368

Townsville Broadband Diabetes Telehealth Trial EVALUATION REPORT. May 2015

Cirrhosis in over 16s

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106

Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227

Technology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta448

Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325

Buprenorphine versus methadone maintenance: a cost-effectiveness analysis Doran C M, Shanahan M, Mattick R P, Ali R, White J, Bell J

Chapter 6 Psychoeducation for depression, anxiety and psychological distress: a meta-analysis

Setting The setting was institutional and tertiary care in London, Essex and Hertfordshire in the UK.

Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S

Setting The setting was primary care. The economic study was conducted in the USA.

Appendix M Health Economic Evidence Extractions

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update

Summary Background 1. Comparative effectiveness of ramucirumab

Setting The setting was secondary care. The economic study was carried out in the UK.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Premeeting briefing Prucalopride for the treatment of chronic constipation in women

Study population The study population comprised adult patients fulfilling the following inclusion criteria:

Technology appraisal guidance Published: 14 December 2016 nice.org.uk/guidance/ta420

CDEC FINAL RECOMMENDATION

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W

Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions Fearon W F, Yeung A C, Lee D P, Yock P G, Heidenreich P A

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta370

Technology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480

Using Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC

Source of effectiveness data The effectiveness evidence came from a review of published studies and the authors' assumptions.

Transcription:

: Computerised cognitive behavioural therapy for panic disorder GRADE evidence profiles versus waitlist control for panic disorder... 2 versus information control for panic disorder... 3 versus any control (waitlist or information control) for panic disorder... 5 versus face-to-face CBT for panic disorder... 6 versus bibliotherapy for panic disorder... 7 1

versus waitlist control for panic disorder assessment Measure of of Life (psychological) (Better indicated by lower values) patients Waitlist control 51 50-51 50-51 50 - Non-panic-free status (clinician and self-report) - Non-remission (1-month post-treatment no longer fulfils panic disorder diagnostic criteria) Discontinuation due to any reason 1 High heterogeneity (>80%) 2 95% confidence interval including no effect Very serious 1 21/51 (41.2%) 5/51 (9.8%) 49/51 (96.1%) RR 0.44 (0.12 to 1.55) 100% 3/50 (6%) 5.8% RR 1.48 (0.2 to 10.79) SMD 1.29 lower (1.72 to 0.86 lower) SMD 0.84 lower (1.39 to 0.29 lower) SMD 0.55 lower (0.95 to 0.15 lower) 538 fewer per 1000 (from 845 fewer to 528 more) 560 fewer per 1000 (from 880 fewer to 550 more) VERY LOW 29 more per 1000 (from 48 fewer to 587 more) 28 more per 1000 (from 46 fewer to 568 more) 2

Health economic profile Internet Psykiatri versus waiting list (model 3) Limitations Applicability comments Incremental cost ( ) 1 2 Time horizon: 1 year Incremental effect ICER ( /effect) 1 Uncertainty 1 115.62 0.052 2,216/QALY Probability of Internet Psykiatri being cost effective at 20,000/QALY: 85.3% 1. Costs expressed in 2009 pounds 2. Limited evidence base (2 RCTs); intervention currently not available in the 3. Analysis conducted to assist guideline development; NHS and personal social services perspective; QALYs estimated based on EQ-5D versus information control for panic disorder assessment Measure of panic severity (Better indicated by lower values) Measure of of life (Psychological) (Better indicated by lower values) 1 Randomised Non-panic-free status (clinician and self-report) patients information control 31 27-31 27-31 27-12 9-9/31 (29%) 25/27 (92.6%) 91.7% RR 0.32 (0.18 to 0.56) SMD 0.1 lower (0.77 lower to 0.58 higher) SMD 1.9 lower (3.04 to 0.76 lower) SMD 0.57 lower (1.1 to 0.04 lower) SMD 0.25 lower (1.12 lower to 0.61 higher) 630 fewer per 1000 (from 407 fewer to 759 fewer) 624 fewer per 1000 (from 403 fewer to 752 fewer) 3

Discontinuation due to any reason 1 95% confidence interval including no effect 2 Moderate heterogeneity (50-80%) 3/31 (9.7%) 7/27 (25.9%) 25% RR 0.42 (0.11 to 1.63) 150 fewer per 1000 (from 231 fewer to 163 more) 145 fewer per 1000 (from 222 fewer to 157 more) Health economic profile Panic online versus information control Klein et al., 2006 Australia (model 1) Limitations Applicability comments Incremental cost ( ) 1 Potentially serious 2 4 Partially applicable 5 Time horizon: 6 weeks Cost-consequence Incremental effect 141 See GRADE clinical profile above ICER ( /effect) 1 Uncertainty 1 Non-applicable No statistical of costs Time horizon: 1 year 354.96 0.046 7,599/QALY Probability of cost effectiveness at 20,000/QALY: 92% 1. Costs converted and uplifted to 2009 pounds, using purchasing power parity (PPP) exchange rates (http://www.oecd.org/std/ppp) and the HCHS inflation index; assuming study cost year 2004 2. Short time horizon; intervention costs only considered; various panic, anxiety and cognition outcomes measured (cost-consequence ) 3. Australian study; narrow perspective (intervention costs only considered); local prices used; no QALYs estimated but outcome measures considered relevant in guideline systematic review of clinical evidence 4. Limited evidence base (2 RCTs); intervention currently not available in the 5. Analysis conducted to assist guideline development; NHS and personal social services perspective; QALYs estimated based on EQ-5D 4

versus any control (waitlist or information control) for panic disorder assessment Measure of panic severity (Better indicated by lower values) Measure of of Life (Psychological) (Better indicated by lower values) 3 Randomised Non-Panic-free status (clinician and self-report) Discontinuation due to any reason 1 Moderate heterogeneity (50-80%) 2 Different comparator 3 95% confidence interval including no effect Serious 3 patients Any control (waitlist or information control) 82 77-82 77-82 77-63 59-30/82 (36.6%) 8/82 (9.8%) 74/78 (94.9%) 94.6% 10/77 (13%) 14.4% RR 0.38 (0.19 to 0.78) RR 0.72 (0.22 to 2.4) SMD 0.7 lower (1.41 lower to 0.01 higher) SMD 1.78 lower (2.26 to 1.31 lower) SMD 0.72 lower (1.05 to 0.4 lower) SMD 0.5 lower (0.86 to 0.14 lower) LOW 588 fewer per 1000 (from 209 fewer to 768 fewer) 587 fewer per 1000 LOW (from 208 fewer to 766 fewer) 36 fewer per 1000 (from 101 fewer to 182 more) LOW 40 fewer per 1000 (from 112 fewer to 202 more) 5

versus face-to-face CBT for panic disorder assessment Measure of of Life - QOL (Psychological) (Better indicated by lower values) Panic-free-status (clinician and self-report) Discontinuation due to any reason 1 Moderate heterogeneity (50-80%) 2 95% confidence interval including no effect patients Face-toface CBT 67 62-70 63-65 62-35/71 (49.3%) 8/71 (11.3%) 33/64 (51.6%) RR 0.95 (0.61 to 1.46) 47.9% 5/64 (7.8%) RR 1.41 (0.48 to 4.2) 8.8% SMD 0.11 higher (0.41 lower to 0.62 higher) SMD 0.13 higher (0.22 lower to 0.47 higher) SMD 0.09 higher (0.26 lower to 0.44 higher) LOW 26 fewer per 1000 (from 201 fewer to 237 more) 24 fewer per 1000 (from 187 fewer to 220 more) 32 more per 1000 (from 41 fewer to 250 more) 36 more per 1000 (from 46 fewer to 282 more) 6

Health economic profile Limitations Applicability comments Incremental cost ( ) 1 Panic Online versus face-to-face CBT Incremental effect ICER ( /effect) 1 Uncertainty 1 (model 2) 2 Internet Psykiatri versus face-to-face CBT Time horizon: 1 year - 303.00-0.023 126,849/QALY Probability of Panic Online being cost effective at 20,000/QALY: 71% (model 4) 2 Time horizon: 1 year - 433.50 0.012 dominant Probability of Internet Psykiatri being cost effective at 20,000/QALY: 95% 1. Costs uplifted to 2009 pounds using the HCHS inflation index. 2. Limited evidence base (1 RCT); intervention currently not available in the 3. Analysis conducted to assist guideline development; NHS and personal social services perspective; QALYs estimated based on EQ-5D versus bibliotherapy for panic disorder Health economic profile Panic Online versus therapist-assisted self-administered CBT Klein et al., 2006 Australia Limitations Applicability comments Incremental cost ( ) 1 Potentially serious 2 Partially Time horizon: 6 weeks Cost-consequence Incremental effect ICER ( /effect) 1 Uncertainty - 14 See GRADE clinical profile above Non-applicable No significant difference in costs 1. Costs converted and uplifted to 2009 pounds, using purchasing power parity (PPP) exchange rates (http://www.oecd.org/std/ppp) and the HCHS inflation index; assuming study cost year 2004. 2. Short time horizon; intervention costs only considered; various panic, anxiety and cognition outcomes measured (cost-consequence ) 3. Australian study; narrow perspective (intervention costs only considered); local prices used; no QALYs estimated but outcome measures considered relevant in guideline systematic review of clinical evidence 7